CA-VELO3D
20.10.2020 15:02:11 CEST | Business Wire | Press release
VELO3D , an innovator in digital manufacturing, announced the expansion of its systems portfolio to include Sapphire XC, an “Extra Capacity” large-format printer that will increase production throughput by 5X and reduce cost-per-part by up to 75%, when compared to the existing Sapphire system.
The company also announced plans to roll-out Sapphire Gen 2, which will be a software and hardware upgrade to the current system. Users can expect an improvement of anywhere between 10-50% in productivity and part-cost metrics when compared to the current Sapphire system. The Sapphire Gen 2 upgrade will be available to retrofit on all installed systems starting in Q2 2021.
The Sapphire product family now includes Sapphire Gen 2, the 1-meter tall Sapphire 1MZ and Sapphire XC—all using the laser powder-bed fusion (LPBF) process with patented capabilities to print without consideration of support structures. Sapphire systems specifically address the aerospace, power generation, and energy markets' unmet needs for quality-assured manufacturing of uncompromised geometries.
"Printing larger parts without the additive manufacturing constraints of support structures is highly attractive to many industrial end-users,” said Benny Buller, founder, and CEO of VELO3D . “For the first time, customers will be able to 3D-print uncompromised geometries, with the highest confidence in part quality, in a large format system. Quality assurance with large scale components is critical because the economic impact of failed builds is very significant. We have demonstrated that our integrated solution is capable of producing a greater yield of high-quality parts, and that foundational technology will transfer to our new Sapphire XC."
Sapphire XC Features
- Larger build volume: Build volume 600mm x 550 mm (compared to 315mm x 400 mm in Sapphire)
- Higher productivity for production: 8 lasers x 1,000W each (compared to 2 lasers x 1,000W in Sapphire)
- Integrated manufacturing process: Fully integrated with Flow™ pre-print software and Assure™ quality control software
- Consistent architecture: Utilizes the same optical-train design, recoater technology, gas-flow technology, and metrology as the current Sapphire. Users can also expect similar material properties as Sapphire
- Qualified material alloys : Compatible alloys include Aluminum F357, Titanium 6AI-4V, INCONEL® 718 and HASTELLOY® X
Sapphire XC Pre-Order
Delivery of Sapphire XC will begin in Q4 2021. Early pre-order of Sapphire XC secures a price and an early manufacturing slot for the system. Existing orders of Sapphire XC will consume all available manufacturing slots for Q4 ’21 and most of Q1 ’22.
Webinar Invitation
To learn more about the value of the Sapphire XC large format system and how it addresses unmet customer needs, register for an informative online fireside chat on Oct 22nd at 10 a.m. Eastern Standard Time. Scott Dunham, Vice President of Research at Smartech Analysis will moderate a discussion with Benny Buller, founder and CEO of VELO3D . Live Q&A from the audience will be included in the webinar.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201020005115/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
